OR WAIT 15 SECS
June 17, 2016.
Licensing deal values in the pharma industry rose by 37.1% year-to-year, from $33.7 billion in 2014 to $46.2 billion in 2015, according to GlobalData.The growth was driven primarily by Sanofi, which struck three licensing deals totaling nearly $9 billion, GlobalData's latest whitepaper states.
The whitepaper reports that there has been a surge in investment of deals in the immuno-oncolgy (I-O) space over the past five years, as immunotherapies have become the pillar of cancer treatment. In the I-O space, Sanofi signed a $2.7 billion deal to co-develop Regeneron’s REGN-2810, a programmed cell death protein 1 (PD-1) inhibitor currently in Phase I testing.
Another important I-O partnership, the report adds, was Pfizer’s $2.9 billion agreement with Merck KGaA to develop and commercialize avelumab (MSB-0010718C), an investigational anti-PD-L1 monoclonal antibody in Phase II development as a potential treatment for multiple metastatic and advanced solid tumors, including breast and prostate cancer.
Global data analyst Gianfranco Zeppetelli commented: “We believe deal prices will continue to rise in 2016, as many big pharma companies look to increase their market share in specific therapeutic areas against their competitors.”